



Janssen will present new data for both approved and investigational oncology compounds at ASCO 2017 Annual Meeting.

19 company-sponsored abstracts have been accepted for presentation, including for **abiraterone acetate, daratumumab and ibrutinib**. Most notably, **Phase 3 pivotal trial results for abiraterone acetate** will be featured in the ASCO Press Briefing on Saturday, June 3rd, which have also been selected for inclusion in the Plenary Session on Sunday, June 4th.

Key Trial Readouts

Abiraterone acetate	<ul style="list-style-type: none"> Phase 3 results assessing abiraterone acetate plus prednisone in newly diagnosed patients with high-risk mHNPC: LATITUDE trial (Abstract LBA3). Data from the LATITUDE trial have also been selected for the Best of ASCO program.
Daratumumab	<ul style="list-style-type: none"> Insights into the longer-term efficacy of the immunotherapy daratumumab in combination with lenalidomide plus dexamethasone (DRd), or bortezomib plus dexamethasone (DVd), in relapsed/ refractory patients with MM, based on cytogenetic risk: Follow-up data from the CASTOR/POLLUX pivotal trials (Abstract 8006) Phase 1b safety and efficacy study of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) for patients with newly diagnosed MM: MMY1001 trial (Abstract 8000)
Ibrutinib	<ul style="list-style-type: none"> Phase 3 safety & efficacy data of the BTK inhibitor ibrutinib in previously treated patients with CLL, including those with genetic abnormalities deletion 11q and deletion 17p: RESONATE Study (Abstract 7510).

CORPORATE COMMUNICATIONS



“We are focused on delivering therapies that not only treat cancer, but aim to intercept and eliminate disease,” said Peter F. Lebowitz, M.D., Ph.D., Oncology Therapeutic Area Head, Janssen Research & Development. “We continue to investigate ways in which our medicines can potentially benefit patients at earlier stages of their disease, and we are excited to share emerging